Literature DB >> 23918666

Evaluation of rhesus monkey and guinea pig hepatic cytosol fractions as models for human aldehyde oxidase.

Kanika V Choughule1, John T Barr, Jeffrey P Jones.   

Abstract

Aldehyde oxidase (AOX) is a cytosolic enzyme expressed across a wide range of species, including guinea pig and rhesus monkey. These species are believed to be the best preclinical models for studying human AOX-mediated metabolism. We compared AOX activity in rhesus monkeys, guinea pigs, and humans using phthalazine and N-[2-(dimethylamino)ethyl]acridone-4-carboxamide (DACA) as substrates and raloxifene as an inhibitor. Michaelis-Menten kinetics was observed for phthalazine oxidation in rhesus monkey, guinea pig, and human liver cytosol, whereas substrate inhibition was seen with DACA oxidase activity in all three livers. Raloxifene inhibited phthalazine and DACA oxidase activity uncompetitively in guinea pig, whereas mixed-mode inhibition was seen in rhesus monkey. Our analysis of the primary sequence alignment of rhesus monkey, guinea pig, and human aldehyde oxidase isoform 1 (AOX1) along with homology modeling has led to the identification of several amino acid residue differences within the active site and substrate entrance channel of AOX1. We speculate that some of these residues might be responsible for the differences observed in activity. Overall, our data indicate that rhesus monkeys and guinea pigs would overestimate intrinsic clearance in humans and would be unsuitable to use as animal models. Our study also showed that AOX metabolism in species is substrate-dependent and no single animal model can be reliably used to predict every drug response in humans.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23918666      PMCID: PMC3781378          DOI: 10.1124/dmd.113.052985

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  29 in total

1.  Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase.

Authors:  N E Austin; S J Baldwin; L Cutler; N Deeks; P J Kelly; M Nash; C E Shardlow; G Stemp; K Thewlis; A Ayrton; P Jeffrey
Journal:  Xenobiotica       Date:  2001 Aug-Sep       Impact factor: 1.908

2.  In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver.

Authors:  M R Rashidi; J A Smith; S E Clarke; C Beedham
Journal:  Drug Metab Dispos       Date:  1997-07       Impact factor: 3.922

3.  Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration.

Authors:  Ch Dittrich; G Greim; M Borner; K Weigang-Köhler; H Huisman; A Amelsberg; A Ehret; J Wanders; A Hanauske; P Fumoleau
Journal:  Eur J Cancer       Date:  2002-05       Impact factor: 9.162

4.  Stereoselective pharmacokinetics of RS-8359, a selective and reversible MAO-A inhibitor, by species-dependent drug-metabolizing enzymes.

Authors:  Wataru Takasaki; Mayumi Yamamura; Akiko Nozaki; Takashi Nitanai; Kunihiro Sasahara; Kunio Itoh; Yorihisa Tanaka
Journal:  Chirality       Date:  2005-03       Impact factor: 2.437

Review 5.  Human liver aldehyde oxidase: inhibition by 239 drugs.

Authors:  R Scott Obach; Phuong Huynh; Mary C Allen; Christine Beedham
Journal:  J Clin Pharmacol       Date:  2004-01       Impact factor: 3.126

6.  Species variation in hepatic aldehyde oxidase activity.

Authors:  C Beedham; S E Bruce; D J Critchley; Y al-Tayib; D J Rance
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Oct-Dec       Impact factor: 2.441

7.  Potent inhibition of human liver aldehyde oxidase by raloxifene.

Authors:  R Scott Obach
Journal:  Drug Metab Dispos       Date:  2004-01       Impact factor: 3.922

Review 8.  Ziprasidone metabolism, aldehyde oxidase, and clinical implications.

Authors:  Christine Beedham; Jeffrey J Miceli; R Scott Obach
Journal:  J Clin Psychopharmacol       Date:  2003-06       Impact factor: 3.153

9.  Design of a novel P450: a functional bacterial-human cytochrome P450 chimera.

Authors:  M Shimoji; H Yin; L Higgins; J P Jones
Journal:  Biochemistry       Date:  1998-06-23       Impact factor: 3.162

10.  Substrate specificity of human liver aldehyde oxidase toward substituted quinazolines and phthalazines: a comparison with hepatic enzyme from guinea pig, rabbit, and baboon.

Authors:  C Beedham; D J Critchley; D J Rance
Journal:  Arch Biochem Biophys       Date:  1995-06-01       Impact factor: 4.013

View more
  10 in total

1.  Inhibition of xanthine oxidase by the aldehyde oxidase inhibitor raloxifene: implications for identifying molybdopterin nitrite reductases.

Authors:  E R Weidert; S O Schoenborn; N Cantu-Medellin; K V Choughule; J P Jones; E E Kelley
Journal:  Nitric Oxide       Date:  2014-01-07       Impact factor: 4.427

2.  Interspecies differences in the metabolism of methotrexate: An insight into the active site differences between human and rabbit aldehyde oxidase.

Authors:  Kanika V Choughule; Carolyn A Joswig-Jones; Jeffrey P Jones
Journal:  Biochem Pharmacol       Date:  2015-05-29       Impact factor: 5.858

3.  A novel in vitro allometric scaling methodology for aldehyde oxidase substrates to enable selection of appropriate species for traditional allometry.

Authors:  Rachel D Crouch; J Matthew Hutzler; J Scott Daniels
Journal:  Xenobiotica       Date:  2017-03-10       Impact factor: 1.908

4.  Inhibition of human aldehyde oxidase activity by diet-derived constituents: structural influence, enzyme-ligand interactions, and clinical relevance.

Authors:  John T Barr; Jeffrey P Jones; Nicholas H Oberlies; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2014-10-17       Impact factor: 3.922

5.  Site-Directed Mutagenesis at the Molybdenum Pterin Cofactor Site of the Human Aldehyde Oxidase: Interrogating the Kinetic Differences Between Human and Cynomolgus Monkey.

Authors:  Armina Abbasi; Carolyn A Joswig-Jones; Jeffrey P Jones
Journal:  Drug Metab Dispos       Date:  2020-10-05       Impact factor: 3.922

6.  Enzyme Kinetics, Pharmacokinetics, and Inhibition of Aldehyde Oxidase.

Authors:  Erickson M Paragas; Kanika Choughule; Jeffrey P Jones; John T Barr
Journal:  Methods Mol Biol       Date:  2021

7.  In vitro oxidative metabolism of 6-mercaptopurine in human liver: insights into the role of the molybdoflavoenzymes aldehyde oxidase, xanthine oxidase, and xanthine dehydrogenase.

Authors:  Kanika V Choughule; Carlo Barnaba; Carolyn A Joswig-Jones; Jeffrey P Jones
Journal:  Drug Metab Dispos       Date:  2014-05-13       Impact factor: 3.922

Review 8.  The reproducibility of biomedical research: Sleepers awake!

Authors:  Stephen A Bustin
Journal:  Biomol Detect Quantif       Date:  2015-01-21

9.  Diethylalkylsulfonamido(4-methoxyphenyl)methyl)phosphonate/phosphonic acid derivatives act as acid phosphatase inhibitors: synthesis accompanied by experimental and molecular modeling assessments.

Authors:  Nahid Alimoradi; Mohammad Reza Ashrafi-Kooshk; Mohsen Shahlaei; Shabnam Maghsoudi; Hadi Adibi; Ross P McGeary; Reza Khodarahmi
Journal:  J Enzyme Inhib Med Chem       Date:  2016-10-21       Impact factor: 5.051

10.  Application of in vitro Drug Metabolism Studies in Chemical Structure Optimization for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).

Authors:  Elias C Padilha; Jianyao Wang; Ed Kerns; Arthur Lee; Wenwei Huang; Jian-Kang Jiang; John McKew; Abdul Mutlib; Rosangela G Peccinini; Paul B Yu; Philip Sanderson; Xin Xu
Journal:  Front Pharmacol       Date:  2019-04-24       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.